OPKO Health, Inc. (OPK) CEO Dr. Phillip Frost on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic DisordersGlobeNewsWire • 11/04/19
Earnings Preview: OPKO Health (OPK) Q3 Earnings Expected to DeclineZacks Investment Research • 11/01/19
Opko and Pfizer announce positive results in late-stage trial of human growth hormone treatmentMarket Watch • 10/21/19
OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone DeficiencyGlobeNewsWire • 08/29/19
OPKO Health, Inc. (OPK) CEO Phillip Frost on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
OPKO Health, Inc. (OPK) CEO Phillip Frost on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19